Literature DB >> 29020007

Novartis trial validates inflammasome as chronic disease driver.

Cormac Sheridan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29020007     DOI: 10.1038/nbt1017-893

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta.

Authors:  Fabio Martinon; Kimberly Burns; Jürg Tschopp
Journal:  Mol Cell       Date:  2002-08       Impact factor: 17.970

2.  A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.

Authors:  Rebecca C Coll; Avril A B Robertson; Jae Jin Chae; Sarah C Higgins; Raúl Muñoz-Planillo; Marco C Inserra; Irina Vetter; Lara S Dungan; Brian G Monks; Andrea Stutz; Daniel E Croker; Mark S Butler; Moritz Haneklaus; Caroline E Sutton; Gabriel Núñez; Eicke Latz; Daniel L Kastner; Kingston H G Mills; Seth L Masters; Kate Schroder; Matthew A Cooper; Luke A J O'Neill
Journal:  Nat Med       Date:  2015-02-16       Impact factor: 53.440

  2 in total
  2 in total

1.  Design, Synthesis and Evaluation of Oxazaborine Inhibitors of the NLRP3 Inflammasome.

Authors:  Alex G Baldwin; Victor S Tapia; Tessa Swanton; Claire S White; James A Beswick; David Brough; Sally Freeman
Journal:  ChemMedChem       Date:  2018-02-05       Impact factor: 3.466

Review 2.  Lipid and Non-lipid Factors Affecting Macrophage Dysfunction and Inflammation in Atherosclerosis.

Authors:  Mark S Gibson; Neuza Domingues; Otilia V Vieira
Journal:  Front Physiol       Date:  2018-06-26       Impact factor: 4.566

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.